Author

T. Tsutsumi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. S. Kibel· 2 shared C. Miao· 2 shared K. W. Mouw· 2 shared L. Jia· 2 shared T. Takai· 2 shared T. Tsujino· 2 shared Z. Szallasi· 2 shared A. D. Choudhury· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. S. Kibel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer

T. Tsujino, T. Takai, K. Hinohara, F. Gui, T. Tsutsumi, X. Bai, C. Miao, C. Feng, B. Gui, S. Sztupinszki, A. Simoneau, N. Xie, L. Fazli, X. Dong, H. Azuma, , L. Jia

This study uses CRISPR screens to identify genetic factors affecting PARP inhibitor sensitivity and resistance in prostate cancer, revealing novel targets and mechanisms.

bioRxiv · Apr 13, 2022 · PreprintCancer Biology

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

c. Miao, T. Tsujino, T. Takai, G. Fu, T. Tsutsumi, Z. Sztupinszki, Z. Szallasi, K. W. Mouw, A. S. Kibel, L. Jia

The paper shows that loss of RNASEH2B makes prostate cancer cells sensitive to PARP inhibitors, but co-deletion with RB1 reduces this sensitivity through BRCA2 upregulation, and ATR inhibition can restore sensitivity.

bioRxiv · Nov 8, 2021Cancer Biology

Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation

T. Tsutsumi, T. Nagaoka, T. Yoshida, L. Wang, S. Kuriyama, Y. Suzuki, Y. Nagata, N. Harada, Y. Kodama, F. Takahashi, Y. Morio, K. Takahashi

This study shows nintedanib reduces vascular remodeling in pulmonary arterial hypertension by inhibiting endothelial mesenchymal transition and smooth muscle cell proliferation.

bioRxiv · Mar 20, 2019Physiology